Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 2.27
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers.
Data is available to registered users only
Buy
Sell